Oncology

The FDA has set a Prescription Drug User Fee Act date of February 17, 2025, to approve vimseltinib for patients with tenosynovial giant cell tumor.

Cancer vaccines may pair well with other forms of immunotherapy in the treatment of patients with cancer, according to Catherine J. Wu, MD.

Complete responses were numerically higher without significance in standard triple antiemetic therapy with olanzapine vs placebo.

Genetic testing may be beneficial post-cancer diagnosis for reducing cancer risk for families with hereditary cancer syndromes and managing treatment.

Results from a retrospective cohort study display evidence of potential benefit from GLP-1RAs for the reduction of 13 obesity-associated cancers for those with type 2 diabetes.

Fertility and sexual health services appear to be offered to cancer survivors less often than other services at CoC-accredited practices.

Julie M. Vose, MD, MBA, looks back at the 2024 ASCO Annual Meeting and highlights key presentations.

Two deaths due to presumed sepsis in patients treated in the DENALI trial led to the clinical holds on the advanced solid tumor treatment.

Joleen Hubbard, MD, explains why allowing access to results can improve patient’s outlook on treatments and understanding of their disease.

The European Medicines Agency will begin a centralized review process for subcutaneous nivolumab across multiple solid tumor indications.

Patients 12 years and older with NTRK gene fusion-positive solid tumors may now receive repotrectinib.

Neil M. Iyengar, MD, focuses on the use of artificial intelligence in the oncology space.

Cathy Bradley, PhD, and Lindsay M. Sabik, PhD, spoke about moving the needle forward in the public health space through research and persistence.

Data support revisiting goals of care conversations with patients with very advanced cancer who have significantly progressed with their disease.

Rates of HPV-related cancers may be decreased in patients under 40 have received an HPV vaccine.

Ted A. James, MD, MHCM, FACS, spoke about integrating artificial intelligence into oncology care.

Patients with cancer who underwent surgery during the COVID-19 pandemic were also more likely to have respiratory complications.

While treatment centered around multiple drug options is common practice in oncology, the use of complementary and medicine alternative medicine is being introduced in the space.

Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.

Findings from a health disparities report may support new policies designed to narrow persistent racial and ethnic disparities in health outcomes.

Additional research may be necessary to validate the efficacy of telehealth interventions in clinical activities for patients with cancer.

Lack of energy, difficulty with sleeping, and pain were some of the most common symptoms reported in older patients with cancer.

“If you were to ask me what the 1 magic thing would be, it would be that we would adopt a concept of 1 team, one fight nationally, and that we would be able to have our structures and our coordination of care.”

Patients with advanced solid tumors may be able to stay on treatment with saruparib longer compared with other approved PARP inhibitors, thereby improving efficacy.

Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.